Expectations have been rising for the commercialization of Lilly’s new drug candidate for Alzheimer’s.

On the 15th (local time), Eli Lilly announced that it will complete filing for approval of its new Alzheimer’s candidate ‘donanemab’ within the first quarter of 2022.

The news was announced at an investor meeting while introducing plans for five new drugs that will be launched within the next two years. Lilly had previously said that an application for approval of donanemab would be made sometime next year.

if Lilly’s donanemab is approved, the addition of donanemab to the market following Biogen’s accelerated approval of Aduhelm in June is expected to intensify co